Mr. George Wentworth reports

DELPHX ANNOUNCES CLOSING OF ADDITIONAL UNITS IN OVER-SUBSCRIBED NON-BROKERED UNIT PRIVATE PLACEMENT

Delphx Capital Markets Inc., further to its news releases dated March 19, 2025, and March 21, 2025, with respect to its non-brokered private placement, has issued an additional 714,286 units at a subscription price of seven cents per unit, for additional gross proceeds of $50,000. Completion of the additional issuance will result in the company having issued an aggregate of 7,276,428 units for aggregate proceeds of $509,350 in the private placement. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of eight cents, for a period of five years from the date of issuance.

Completion of the offering is subject to the approval of the TSX Venture Exchange. The securities issued pursuant to the offering will be subject to a hold period of four months plus one day from the date of issuance.

Delphx intends to use the net proceeds from the offering in connection with general corporate purposes.

About Delphx Capital Markets Inc.

Delphx is a technology and financial services company focused on developing and distributing the next generation of structured products. Through its special-purpose vehicle, Quantem LLC, the company enables fixed income dealers to offer new private placement securities that provide mitigation of spread and capital charge losses when downgrades occur, while allowing for attractive returns. The new Delphx securities will enable dealers and their qualified institutional investors (QIBs) accounts to competitively structure, sell and make markets in: collateralized put options (CPOs) that provide secured rating downgrade protection for underlying corporate bonds; and collateralized reference notes (CRNs) that enable investors to take on a capped rating downgrade exposure of an underlying security in exchange for attractive returns.

All CPOs and CRNs are fully collateralized and held in custody by U.S. Bank. CPOs and CRNs are proprietary products created and owned by Delphx Capital Markets.